The U.S. Food and Drug Administration has approved gedatolisib, marketed as Revtorpyk, in combination with the hormone therapy fulvestrant—with or without the targeted drug palbociclib—for adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer. The clearance, announced in mid-July 2026, gives oncologists a new option for a common and difficult-to-treat form of the disease.
Who the approval is for
The decision specifically addresses patients whose cancer has progressed after endocrine therapy and who do not carry a mutation in the PIK3CA gene. That is an important subgroup. Much of the recent innovation in this space has targeted PIK3CA-mutant tumors, leaving patients without that mutation with fewer tailored choices once first-line hormone treatment stops working. Gedatolisib is designed to inhibit multiple nodes along the PI3K/AKT/mTOR signaling pathway, a network that cancer cells frequently hijack to keep growing.
The trial behind the decision
Approval rested on the VIKTORIA-1 trial, and the numbers were striking. Patients receiving the triplet regimen—gedatolisib, fulvestrant and palbociclib—saw median progression-free survival of 9.3 months, compared with just 2.0 months for those given fulvestrant alone. Progression-free survival measures how long patients live without their disease worsening, and a gap of that size is clinically meaningful in a setting where options are limited.
Why it matters
HR-positive, HER2-negative disease accounts for the majority of breast cancer diagnoses. When it becomes advanced, treatment becomes a sequence of decisions aimed at holding the cancer in check for as long as possible while preserving quality of life. Each additional effective regimen extends that sequence and buys patients time.
- Mechanism: blocks several points in the PI3K/AKT/mTOR growth pathway at once.
- Population: HR-positive, HER2-negative advanced disease without a PIK3CA mutation, after prior endocrine therapy.
- Evidence: a large improvement in progression-free survival versus fulvestrant alone.
The broader context
The gedatolisib approval arrived during an unusually active stretch for cancer and kidney drug regulation. In the same window, the FDA cleared new pembrolizumab-based regimens for muscle-invasive bladder cancer and approved a first-in-class therapy for a form of kidney disease. Together they reflect a regulatory pipeline moving steadily on hard-to-treat conditions.
As with any new combination, oncologists will weigh side effects and cost against the survival benefit, and real-world use will refine which patients gain the most. But for people facing HR-positive, HER2-negative breast cancer that no longer responds to hormone therapy, the arrival of a mechanistically distinct option is welcome news—and a reminder that incremental, evidence-driven progress remains the engine of modern oncology.